NEW YORK (GenomeWeb News) – Agilent Technologies and Seoul National University Hospital in South Korea are collaborating to develop and verify biomarkers for use in developing drugs, they announced Wednesday.

Drugs to be developed as part of the deal include narcotics and immune suppressants.

Agilent is supplying its 6460 Triple Quadrupole LC/MS system, as well as support services and application expertise to the work. The hospital will create and maintain "an optimal environment for new biomarkers to be identified and tested vigorously," the partners said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.